Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
A phase 2 trial of Pixantrone, Ifosfamide, Etoposide and Rituximab in Non-Hodgkin lymphoma, run by The Lymphoma Academic Research Organisation, completed.
Overview
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma is a phase 2 interventional study registered as NCT03458260 by The Lymphoma Academic Research Organisation, with 74 participants recorded, started 2018-12-26 and reaching its primary completion in 2024-12-24. Interventions recorded: Pixantrone, Ifosfamide, Etoposide, Rituximab, Transplant. Conditions recorded: Aggressive Non-Hodgkin Lymphoma.
Linked to the drug Pixantrone because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Shares Pixantrone and the tag pipeline.
- TrialIbritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialTreatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Shares Ifosfamide, Etoposide, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.